10
Apr
2018

Update Regarding the FDA Submission for Coagulation Factor VIIa (Recombinant), activated eptacog beta*

by John Holt | with no comments | Uncategorized

On January 9, 2017, HEMA Biologics, LLC announced Food and Drug Administration (FDA) acceptance of the Biologics License Application (BLA),...

- Continue Reading
13
Sep
2017

Bleeding Disorders Awareness Month at HEMA Biologics

by John Holt | with no comments | Uncategorized

Pictured above are some highlights from March. We loved seeing how our team incorporated bleeding disorder awareness into their everyday...

- Continue Reading
13
Sep
2017

HEMA Biologics Connects With the Community at HFA

by John Holt | with no comments | Uncategorized

[caption id="attachment_524" align="alignnone" width="300"] Pictured at our HFA Booth, from left to right: HEMA Biologics’ Whitney Mardis, Mary Norton, Kate...

- Continue Reading
13
Sep
2017

Texas Bleeding Disorders Conference

by John Holt | with no comments | Uncategorized

[caption id="attachment_528" align="alignleft" width="300"] Vince Poma, Dr Marsh, Blake Buckman, and Elyse Bergeron at our booth, before visitors came by...

- Continue Reading
13
Sep
2017

National Hemophilia Foundation’s 69th Annual Meeting

by John Holt | with no comments | Uncategorized

This August was our second year at NHF’s Annual Meeting — an incredible venue for meeting the community and learning...

- Continue Reading
03
Mar
2017

HEMA Biologics heading to Providence, RI for the HFA annual meeting – April 6, 2017

by John Holt | with no comments | Uncategorized

From HFA’s site: HFA's Annual Symposium is a community-centered educational event that draws hundreds of members from the bleeding disorders...

- Continue Reading
02
Mar
2017

FDA accepts the submitted Biologic License Application for Coagulation Factor VIIa (Recombinant), activated eptacog beta – Jan. 9, 2017

by John Holt | with no comments | Uncategorized

LOUISVILLE, Ky., Jan. 9, 2017 /PRNewswire/ -- HEMA Biologics, LLC announced that the FDA has accepted the BLA for their first...

- Continue Reading